Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
imlunestrant + trastuzumab
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral, Subcutaneous
01
Overview
Imlunestrant + trastuzumab is an investigational combination therapy for the treatment of estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–positive (HER2+) advanced breast cancer. Imlunestrant is a next-generation oral selective estrogen receptor degrader (SERD) that binds to and degrades the estrogen receptor, leading to inhibition of ER signaling—including in cancers with ESR1 mutations. Trastuzumab is a monoclonal antibody targeting HER2 and inhibits HER2-mediated signaling pathways. The combination aims to simultaneously block both ER and HER2 pathways in patients whose tumors express both targets. Early-phase clinical trials have shown that this combination is well tolerated with manageable side effects and demonstrates preliminary antitumor activity in patients with ER+/HER2+ advanced breast cancer who have received prior therapies[1].
- Other names
- imlunestrant + Herceptin
02
Targets
ESR1 (ERα)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on imlunestrant + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on imlunestrant + trastuzumab.